Patient and transplant demographics (n = 124)
| Characteristic . | Value . |
|---|---|
| Age, y | |
| Median | 8 |
| Range | 0.4-32 |
| Diagnosis, n (%) | |
| Malignancy | 33 (26) |
| Immune deficiency | 44 (36) |
| Bone marrow failure | 47 (38) |
| Conditioning regimens, n (%) | |
| Myeloablative | 72 (58) |
| Reduced intensity | 52 (42) |
| Stem cell source, n (%) | |
| BM | 104 (84) |
| PBSC | 14 (11) |
| CB | 6 (5) |
| Cell dose | |
| Median | 6.8 × 108 cells/kg |
| Range | 15.4 × 106-32.75 × 108 cells/kg |
| Donor, n (%) | |
| Related | 47 (38) |
| Unrelated | 77 (62) |
| Match, n (%) | |
| BM and PBSC | |
| 10/10 | 92 (74) |
| 9/10 | 23 (19) |
| 8/10 | 3 (2) |
| CB | |
| 6/6 | 2 (1) |
| 5/6 | 2 (1) |
| 4/6 | 2 (1) |
| GVHD prophylaxis, n (%) | |
| CSA ± other | 108 (87) |
| Tacrolimus ± other | 5 (4) |
| Ex-vivo T-cell depletion | 9 (7) |
| Other | 2 (2) |
| Characteristic . | Value . |
|---|---|
| Age, y | |
| Median | 8 |
| Range | 0.4-32 |
| Diagnosis, n (%) | |
| Malignancy | 33 (26) |
| Immune deficiency | 44 (36) |
| Bone marrow failure | 47 (38) |
| Conditioning regimens, n (%) | |
| Myeloablative | 72 (58) |
| Reduced intensity | 52 (42) |
| Stem cell source, n (%) | |
| BM | 104 (84) |
| PBSC | 14 (11) |
| CB | 6 (5) |
| Cell dose | |
| Median | 6.8 × 108 cells/kg |
| Range | 15.4 × 106-32.75 × 108 cells/kg |
| Donor, n (%) | |
| Related | 47 (38) |
| Unrelated | 77 (62) |
| Match, n (%) | |
| BM and PBSC | |
| 10/10 | 92 (74) |
| 9/10 | 23 (19) |
| 8/10 | 3 (2) |
| CB | |
| 6/6 | 2 (1) |
| 5/6 | 2 (1) |
| 4/6 | 2 (1) |
| GVHD prophylaxis, n (%) | |
| CSA ± other | 108 (87) |
| Tacrolimus ± other | 5 (4) |
| Ex-vivo T-cell depletion | 9 (7) |
| Other | 2 (2) |
BM, bone marrow; CB, cord blood; CSA, cyclosporine; PBSC, peripheral blood stem cell.